<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01211535</url>
  </required_header>
  <id_info>
    <org_study_id>SMA-09-59</org_study_id>
    <nct_id>NCT01211535</nct_id>
  </id_info>
  <brief_title>Subjective Comfort With Multipurpose Care Solutions in Soft Contact Lens Wearers</brief_title>
  <official_title>Subjective Comfort With Multipurpose Care Solutions in Soft Contact Lens Wearers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to assess the comfort of OPTI-FREE RepleniSH in soft contact
      lens wearers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline (Day 0) in Ocular Comfort Rating at Day 14</measure>
    <time_frame>Baseline (Day 0), Day 14</time_frame>
    <description>Ocular comfort was rated by the participant on a continuous visual analog scale from 0-100, where 0=extremely uncomfortable, 50=neither comfortable nor uncomfortable, and 100=extremely comfortable. The participant marked a horizontal line across the scale at the point that best described, &quot;how your eyes feel right now.&quot; A positive number indicates increased ocular comfort; a negative number indicates decreased ocular comfort.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Myopia</condition>
  <condition>Astigmatism</condition>
  <condition>Refractive Error</condition>
  <arm_group>
    <arm_group_label>OPTI-FREE RepleniSH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPTI-FREE RepleniSH multipurpose solution used with study contact lenses on a daily wear basis for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ReNu Biotrue</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ReNu Biotrue multipurpose solution used with study contact lenses on a daily wear basis for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OPTI-FREE RepleniSH multipurpose solution</intervention_name>
    <description>FDA-approved, multipurpose solution used as indicated for cleaning, rinsing, conditioning, disinfecting, and storing study contact lenses on a daily wear basis for 14 days</description>
    <arm_group_label>OPTI-FREE RepleniSH</arm_group_label>
    <other_name>OPTI-FREE® RepleniSH®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ReNu Biotrue multipurpose solution</intervention_name>
    <description>FDA-approved, multipurpose solution used as indicated for cleaning, disinfecting, daily protein removing, and storing study contact lenses on a daily wear basis for 14 days</description>
    <arm_group_label>ReNu Biotrue</arm_group_label>
    <other_name>ReNu Biotrue™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Silicone hydrogel contact lenses</intervention_name>
    <description>Silicone hydrogel contact lenses per subject's habitual brand and prescription worn on a daily wear basis for 14 days, with either OPTI-FREE RepleniSH or ReNu Biotrue used for contact lens care</description>
    <arm_group_label>OPTI-FREE RepleniSH</arm_group_label>
    <arm_group_label>ReNu Biotrue</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Currently wearing silicone hydrogel contact lenses on a daily wear basis;

          -  Currently using OPTI-FREE RepleniSH contact lens solution;

          -  Generally healthy;

          -  Normal ocular health;

          -  Willing to follow study procedures and visit schedule;

          -  Sign Informed Consent and privacy document;

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Use of additional lens cleaners;

          -  Known sensitivities to any ingredient in either test article;

          -  Systemic or ocular disease or disorder that would negatively affect the conduct or
             outcome of the study;

          -  History of ocular surgery/trauma within the last 6 months;

          -  Any topical ocular or systemic antibiotics within 7 days of enrollment continuing
             throughout the study;

          -  Participation in any other ophthalmic drug or device clinical trial within 30 days of
             enrollent;

          -  Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Contact Alcon Trial Center for Trial Locations</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2010</study_first_submitted>
  <study_first_submitted_qc>September 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2010</study_first_posted>
  <results_first_submitted>October 15, 2012</results_first_submitted>
  <results_first_submitted_qc>October 15, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 12, 2012</results_first_posted>
  <last_update_submitted>October 15, 2012</last_update_submitted>
  <last_update_submitted_qc>October 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Soft contact lenses</keyword>
  <keyword>Multi-purpose Solution</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Astigmatism</mesh_term>
    <mesh_term>Refractive Errors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>OPTI-FREE RepleniSH</title>
          <description>OPTI-FREE RepleniSH multipurpose solution used with study contact lenses on a daily wear basis for 14 days</description>
        </group>
        <group group_id="P2">
          <title>ReNu Biotrue</title>
          <description>ReNu Biotrue multipurpose solution used with study contact lenses on a daily wear basis for 14 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>OPTI-FREE RepleniSH</title>
          <description>OPTI-FREE RepleniSH multipurpose solution used with study contact lenses on a daily wear basis for 14 days</description>
        </group>
        <group group_id="B2">
          <title>ReNu Biotrue</title>
          <description>ReNu Biotrue multipurpose solution used with study contact lenses on a daily wear basis for 14 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
            <count group_id="B2" value="52"/>
            <count group_id="B3" value="104"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.3" spread="10.4"/>
                    <measurement group_id="B2" value="35.4" spread="10.96"/>
                    <measurement group_id="B3" value="34.3" spread="10.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline (Day 0) in Ocular Comfort Rating at Day 14</title>
        <description>Ocular comfort was rated by the participant on a continuous visual analog scale from 0-100, where 0=extremely uncomfortable, 50=neither comfortable nor uncomfortable, and 100=extremely comfortable. The participant marked a horizontal line across the scale at the point that best described, &quot;how your eyes feel right now.&quot; A positive number indicates increased ocular comfort; a negative number indicates decreased ocular comfort.</description>
        <time_frame>Baseline (Day 0), Day 14</time_frame>
        <population>All participants who received regimen, satisfied inclusion/exclusion criteria, and completed the 14-day treatment period (per protocol)</population>
        <group_list>
          <group group_id="O1">
            <title>OPTI-FREE RepleniSH</title>
            <description>OPTI-FREE RepleniSH multipurpose solution used with study contact lenses on a daily wear basis for 14 days</description>
          </group>
          <group group_id="O2">
            <title>ReNu Biotrue</title>
            <description>ReNu Biotrue multipurpose solution used with study contact lenses on a daily wear basis for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline (Day 0) in Ocular Comfort Rating at Day 14</title>
          <description>Ocular comfort was rated by the participant on a continuous visual analog scale from 0-100, where 0=extremely uncomfortable, 50=neither comfortable nor uncomfortable, and 100=extremely comfortable. The participant marked a horizontal line across the scale at the point that best described, &quot;how your eyes feel right now.&quot; A positive number indicates increased ocular comfort; a negative number indicates decreased ocular comfort.</description>
          <population>All participants who received regimen, satisfied inclusion/exclusion criteria, and completed the 14-day treatment period (per protocol)</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.40" lower_limit="83.82" upper_limit="90.99"/>
                    <measurement group_id="O2" value="88.79" lower_limit="85.21" upper_limit="92.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.75" lower_limit="78.17" upper_limit="85.33"/>
                    <measurement group_id="O2" value="83.18" lower_limit="79.56" upper_limit="86.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (Day 0) at Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.65" lower_limit="-10.72" upper_limit="-0.59"/>
                    <measurement group_id="O2" value="-5.61" lower_limit="-10.70" upper_limit="-0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for the duration of the study.</time_frame>
      <desc>The safety population includes all participants who received study regimen.</desc>
      <group_list>
        <group group_id="E1">
          <title>OPTI-FREE RepleniSH</title>
          <description>OPTI-FREE RepleniSH multipurpose solution used with study contact lenses on a daily wear basis for 14 days</description>
        </group>
        <group group_id="E2">
          <title>ReNu Biotrue</title>
          <description>ReNu Biotrue multipurpose solution used with study contact lenses on a daily wear basis for 14 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jami Kern, Ph.D.</name_or_title>
      <organization>Alcon Global Medical Affairs</organization>
      <phone>1-888-451-3937</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

